Current status and prospects of androgen depletion therapy for prostate cancer

References 

1. Akaza H. Trends in primary androgen depletion therapy for patients with localized and locally advanced prostate cancer: Japanese perspective. Cancer Science. 2006;97:243–247
   • MEDLINE
   • CrossRef
2. Japanese Urological Association . The prostate cancer treatment guideline 2006. KANEHARA & CO., LTD.; 2006;
3. Mulrow C, Langhome P, Grimshaw J. Integrating heterogeneous pieces of evidence in systematic reviews. Annals of Internal Medicine. 1997;127:989–995
   • MEDLINE
4. Cancer Registration Committee of the Japanese Urological Association . Clinicopathological statistics on registered prostate cancer patients in Japan: 2000 report from the Japanese Urological Association. International Journal Urology. 2005;12:46–61
5. Akaza H, Hinotsu S, Usami M, et al. Characteristics of patients with prostate cancer who have initially been treated by hormone therapy in Japan: J-CaP surveillance. Japanese Journal of Clinical Oncology. 2004;34:329–336
   • MEDLINE
   • CrossRef
6. Cooperberg MR, Grossfeld GD, Lubeck DF, et al. National practice patterns and time trends in androgen ablation for localized prostate cancer. Journal of the National Cancer Institute. 2003;95:981–989
   • CrossRef
7. Fleming C, Wasson JH, Albertsen PC, et al. A decision analysis of alternative treatment strategies for clinically localized prostate cancer. Prostate Patient Outcomes Research Team. JAMA. 1993;269:2650–2658
   • MEDLINE
8. Miller DC, Gruber SB, Hollenbeck BK, et al. Incidence of initial local therapy among men with lower-risk prostate cancer in the United States. Journal of the National Cancer Institute. 2006;98:1134–1141
   • CrossRef
9. Loblaw DA, Virgo KS, Nam R, et al. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. Journal of Clinical Oncology. 2007;25:1596–1605[Epub 2007 Apr 2]
10. Akaza H, Yamaguchi A, Matsuda T, et al. Superior anti-tumor efficacy of bicalutamide 80.mg in combination with a luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist monotherapy as first-line treatment for advanced prostate cancer: interim results of a randomized study in Japanese patients. Japanese Journal of Clinical Oncology. 2004;34:20–28
    • MEDLINE
    • CrossRef
11. Usami M, Akaza H, Arai Y, et al. Bicalutamide 80.mg combined with a luteinizing hormone-releasing hormone agonist (LHRH-A) versus LHRH-A monotherapy in advanced prostate cancer: findings from a phase III randomized, double-blind, multi-center trial in Japanese patients. Prostate Cancer and Prostatic Diseases. 2007;10:194–201
    • MEDLINE
    • CrossRef
12. Hinotsu S, Akaza H, Usami M, et al. Combined androgen blockade (CAB) with bicalutamide and a luteinizing hormone-releasing hormone agonist (LHRH-A) versus LHRH-A monotherapy in Japanese patients with advanced prostate cancer: long-term follow-up reporting overall and cause-specific survival. In: First European multidisciplinary meeting on Urological Cancers. 2007 [abstract 119].
13. Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA. 2005;293:2095–2101
    • CrossRef
14. Thompson IM, Pauler Ankerst D, Coltman CA, et al. Prediction of prostate cancer for patients receiving finasteride: results from the Prostae Cancer Prevention Trial. Journal of Clinical Oncology. 2007;25:2999–3000